Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Grupo Español de Investigación en Cáncer de Ovario
Age
70–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Written informed consent must be signed by all patients participating in the study who can be interviewed in the hospital (accessible, alive patients) or absence of consent sheet must be signed by the investigator. Informed consent may not be required from unaccesible patients (dead, lost, etc.) according to ethics committee permissions and applicable law for retrospective studies in Spain.
Adult women (≥70 years at the time of treatment initiation with trabectedin and PLD).
Histological diagnosis of platinum-sensitive relapsed ovarian cancer (PFI ≥ 6 months).
Treatment started with trabectedin and PLD (at least one cycle) as standard of care between January 1st 2015 and December 31st 2019.
Patients must have received at least one cycle of trabectedin + PLD.
You may not be if
Patients without medical record available (lost, empty or unretrievable clinical information).
Patients who explicitly refuse to participate in the study.